Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03616535
Other study ID # IRB00152858
Secondary ID R01DK114074
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 30, 2018
Est. completion date December 8, 2024

Study information

Verified date January 2024
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, controlled trial to slow cognitive decline in adults undergoing hemodialysis (HD). The investigators will test three interventions cognitive training (CT), exercise training (ET), and combined cognitive and exercise training (CT+ET) relative to standard of care (SC).


Description:

This will be a two by two factorial, randomized, controlled trial to slow cognitive decline in adults undergoing hemodialysis (HD). The investigators primary objective is to determine if receiving cognitive training (tablet-based brain games), exercise training (stationary foot pedal), or combined cognitive and exercise training preserves executive function relative to those with standard of care . The secondary objectives are to compare the rates of end stage renal disease (ESRD)-specific clinical outcomes and patient centered outcomes among those receiving CT, or ET, or CT+ET relative to those in SC. The investigators will formally test whether receiving CT or ET will preserve executive function and receiving combined CT+ET will preserve executive function better than CT or ET alone.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 121
Est. completion date December 8, 2024
Est. primary completion date December 8, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older at enrollment - English speaking - within 3 months to 3 years of initiating hemodialysis - receiving hemodialysis at participating dialysis centers Exclusion Criteria: Patients with the following conditions will be excluded: - Pregnancy - Angina Pectoris - Chronic lung disease requiring oxygen - Musculoskeletal conditions that limit mobility - Upper or lower extremity amputation - Orthopedic disorders exacerbated by physical activity - Femoral arteriovenous (AV) access - Hepatitis B infection - Blindness/Legal blindness In addition to conditions outlined above, patients who are currently incarcerated will be excluded from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Cognitive training
The investigators will provide participants with tablets to play brain games.
Exercise training
The investigators will provide participants with foot peddlers.
Combined cognitive and exercise training
The investigators will provide participants with tablets to play brain games for cognitive training and stationary foot peddlers for exercise training.

Locations

Country Name City State
United States Johns Hopkins School of Medicine Baltimore Maryland
United States New York University Langone Health New York New York

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in executive function as assessed by the Trail Making Test Change in executive function between baseline and 3 months as assessed by the Trail Making Test which is comprised of Part A and Part B. Executive function is assessed by the time (minutes) to complete Part B minus the time (minutes) to complete Part A. Needing more time to complete the test indicates worse executive function. 3 months
Secondary Change in Global Cognitive Function as measured by the Montreal Cognitive Assessment (MoCA) Change in global cognitive function at 3-months and 6 months of interventions as measured by the Montreal Cognitive Assessment (MoCA). It is a brief 30 question test that assesses different cognitive domains: attention and concentration, executive functions, memory, language, visual construction skills, conceptual thinking, calculations, and orientation. Total possible score is 30 points and a score of 26 or above is considered normal. 3 months and 6 months
Secondary Change in Executive function as measured by the Stroop test Change in executive function at 3 months and 6 months of interventions as measured by the Stroop Test. The Stroop test is a screening test for cognitive function test and evaluates the inhibitory control of executive function. It is a measure of the ability of the brain to sort out distracting or unnecessary information from the meaningful tasks. It involves reading the name of a color printed in a different color ink. The time ratio of color-word interference and color only tasks will be calculated. 3 months and 6 months
Secondary Change in Executive function as measured by the Digit Symbol Substitution Test Change in executive function at 3 months and 6 months of interventions as measure by the Digit Symbol Substitution Test. This test evaluates the speed and working memory components of executive function. It involves a key consisting of the numbers 1-9, each paired with a unique, easy-to--draw symbol such as a "V", "+" or ">". Below the key are a series of the numbers 1-9 in random order and repeated several times. The participant is allowed 90 seconds to fill in the corresponding symbol for each number. This task requires the individual to visually scan the answer key provided at the top of the test and then write the correct symbol by each number as quickly as possible. The correct number of symbols written within 90 seconds is measured. 3 months and 6 months
Secondary Change in Physical function as measured by the Short Physical Performance Battery (SPPB) test Change in lower extremity function at 3 months and 6 months of interventions using the SPPB test. The SPPB is an objective assessment tool for evaluating lower extremity functioning This test is a performance-based assessment comprised of 3 tasks: 1) repeated chair stands, 2) standing balance, and 3) a 4-meter usual paced walk in those with and without a walking aid (meters/second). Participants receive a score of 0 for a task if they were unable to complete the task; otherwise, they receive scores of 1-4 based on population-based norms. The scores of the three tasks are summed to create the SPPB score. The SPPB score ranges from 0 to 12, with lower scores indicating poorer function. 3 months and 6 months
Secondary Number of Falls Number of injurious falls resulting in a medical encounter during the 6 months of interventions and for 6 months after the interventions 12 months
Secondary Number of Hospitalizations The number of hospitalizations parameterized as both the number of hospital admissions and number of days hospitalized during the 6 months of interventions and 6 months after the interventions 12 months
Secondary Mortality Mortality will be captured through Center for Medicare and Medicaid Services (CMS) death notification or the National Death Index. Mortality will be ascertained within the 6 months of the intervention and 1 year after the intervention (1.5 years total). 18 months
Secondary Change in Patient-centered Outcomes as measured by the Kidney Disease Quality of Life (KDQOL) Survey Change in kidney disease-specific physical and mental quality of life at 3 months and 6 months of interventions. The KDQOL s a kidney disease-specific measure of how kidney disease is impacting a participant's quality of life. It is a 36-item survey with 3 subscales including physical and mental health-related quality of life, and kidney disease-specific HRQOL. Each subscale is scored 0 to 100 with higher scores indicating better HRQOL. 3 months and 6 months
Secondary Change in Patient-centered Outcomes as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Change in the participants' physical, mental, and social health status at 3 months and 6 months of interventions. PROMIS-29 is a health-related quality of life survey which assesses each of the 7 PROMIS domains with 4 questions. Norm-based scores have been calculated for each domain on the PROMIS measures. High scores represent more of the domain being measured. Thus, on symptom-oriented domains of PROMIS-29 (anxiety, depression, fatigue, pain interference, and sleep disturbance), higher scores represent worse symptomatology. On the function-oriented domains (physical functioning and social role) higher scores represent better functioning. 3 months and 6 months
Secondary Number of Amputations The number of amputations during the 6 months of interventions and 6 months after interventions. This information will be either self-reported by the participant or abstracted from the medical records to see if the interventions are associated with amputations 12 months
Secondary Number of Participants Able to Return to Work The number of participants able to return to work during the 6 months of interventions and 6 months after interventions. 12 months
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT03943212 - The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis N/A
Completed NCT03456648 - Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study Phase 2
Completed NCT00966615 - The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition Phase 4
Completed NCT01252771 - Phosphate Kinetic Modeling 2 Phase 4
Completed NCT00850252 - Use of a Lifeline Graft in the A-V Shunt Model Phase 1/Phase 2
Completed NCT00294502 - Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia Phase 4
Completed NCT05011136 - Physician Reimbursement Home Patients
Completed NCT05144971 - StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Completed NCT02278562 - Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2 Phase 2
Completed NCT01424787 - Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering) N/A
Terminated NCT00580762 - Bariatric Surgery for ESRD Patients vs Control N/A
Recruiting NCT05339139 - SAfety of Regional Citrate Anticoagulation (SARCA Study) Phase 3
Completed NCT03242343 - VasQ External Support for Arteriovenous Fistula N/A
Recruiting NCT05309785 - Safety and Efficacy of Canagliflozin in Advanced CKD Phase 4
Completed NCT02966028 - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) Phase 2
Not yet recruiting NCT02596386 - Examination of Potassium Levels in Saliva in ESRD Patients N/A
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Active, not recruiting NCT02270515 - Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease N/A
Recruiting NCT06001827 - SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study N/A